-
1دورية أكاديمية
المؤلفون: Aya Nishizawa, Misaki Kawakami, Yasuyuki Kitahara
المصدر: Frontiers in Oncology, Vol 14 (2024)
مصطلحات موضوعية: metastatic malignant melanoma, BRAFV600 mutation-positive melanoma, immune checkpoint inhibitor, BRAF/MEK inhibitors, heart failure, COVID-19 vaccination, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3
المؤلفون: Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, Gabriela Cinat, Luis Enrique Fein, Michael Brown, Andrew Haydon, Adnan Khattak, Catriona McNeil, Phillip Parente, Jeremy Power, Rachel Roberts-Thomson, Shahneen Sandhu, Craig Underhill, Suresh Varma, Thomas Berger, Ahmad Awada, Nathalie Blockx, Veronique Buyse, Jeroen Mebis, Fábio André Franke, Sérgio Jobim de Azevedo, Nicolas Silva Lazaretti, Rahima Jamal, Catalin Mihalcioiu, Teresa Petrella, Kerry Savage, Xinni Song, Ralph Wong, Nina Dabelic, Stjepko Plestina, Zeljko Vojnovic, Petr Arenberger, Ivo Kocak, Ivana Krajsova, Eugen Kubala, Bohuslav Melichar, Yvetta Vantuchova, Kadri Putnik, Brigitte Dreno, Caroline Dutriaux, Jean-Jacques Grob, Pascal Joly, Jean-Philippe Lacour, Nicolas Meyer, Laurent Mortier, Luc Thomas, Michael Fluck, Thilo Gambichler, Jessica Hassel, Axel Hauschild, Paul Donnellan, John McCaffrey, Derek Power, Samuel Ariad, Gil Bar-Sela, Daniel Hendler, Ilan Ron, Jacob Schachter, Paolo Ascierto, Alfredo Berruti, Luca Bianchi, Vanna Chiarion Sileni, Francesco Cognetti, Riccardo Danielli, Anna Maria Di Giacomo, Luca Gianni, Aron Goldhirsch, Michele Guida, Paolo Marchetti, Paola Queirolo, Armando Santoro, Ellen Kapiteijn, Paula Ferreira, Georgy Gafton, Yulia Makarova, Zoran Andric, Nada Babovic, Darjana Jovanovic, Lidija Kandolf Sekulovic, Graham Cohen, Lydia Dreosti, Daniel Vorobiof, Maria Teresa Curiel Garcia, Roberto Diaz Beveridge, Margarita Majem Tarruella, Ivan Marquez Rodas, Jose-M Puliats Rodriguez, Antonio Rueda Dominguez, Marianne Maroti, Karin Papworth, Olivier Michielin, Ewan Brown, Pippa Corrie, Mark Harries, Satish Kumar, Agustin Martin-Clavijo, Mark Middleton, Poulam Patel, Toby Talbot, Sanjiv Agarwala, Paul Chapman, Robert Conry, Gary Doolittle, Tara Gangadhar, Sigrun Hallmeyer, Omid Hamid, Leonel Hernandez-Aya, Douglas Johnson, Frederic Kass, Tatjana Kolevska, Scott Lunin, April Salama, Branimir Sikic, Bradley Somer, David Spigel, Eric Whitman
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, mutation-positive melanoma, Population, Placebo, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Clinical endpoint, medicine, education, Vemurafenib, Survival analysis, vemurafenib, BRAFV600, mutation-positive melanoma, education.field_of_study, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, Hazard ratio, Regimen, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, BRAFV600, Cohort, vemurafenib, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ca377ad3c682462789b57095f06c16
http://hdl.handle.net/11379/501841 -
4
المؤلفون: Djura Piersma, Alfons J.M. van den Eertwegh, Alexander C.J. van Akkooi, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, John B. A. G. Haanen, Gerard Vreugdenhil, M Schouwenburg, Ellen Kapiteijn, Michel W.J.M. Wouters, Geke A. P. Hospers, Karijn P M Suijkerbuijk, Jan Willem B. de Groot, Willeke A. M. Blokx, Rozemarijn S. van Rijn, Albert J. ten Tije, A Jochems, B Leeneman, Maureen J.B. Aarts, Wim H. J. Kruit, Rutger H. T. Koornstra, Michiel C T van Zeijl, Margreet G. Franken, Marieke W. J. Louwman
المساهمون: Health Technology Assessment (HTA), Medical Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), CCA - Cancer Treatment and quality of life, Medical oncology, AII - Inflammatory diseases
المصدر: Melanoma Research, 28, 326-332
Melanoma Research, 28, 4, pp. 326-332
Melanoma Research, 28(4), 326-332. Lippincott Williams & Wilkins
Melanoma Research, 28(4), 326-332. LIPPINCOTT WILLIAMS & WILKINS
Melanoma Research, 28(4), 326. Lippincott Williams and Wilkins
Schouwenburg, M G, Jochems, A, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, van Zeijl, M C T, Aarts, M J, van Akkooi, A C J, van den Berkmortel, F W P J, Blokx, W A M, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2018, ' Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes ', Melanoma Research, vol. 28, no. 4, pp. 326-332 . https://doi.org/10.1097/CMR.0000000000000453
Melanoma Research, 28(4), 326-332. Lippincott Williams and Wilkins
Melanoma Research, 28(4), 326-332مصطلحات موضوعية: Male, Oncology, Cancer Research, Skin Neoplasms, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], MULTICENTER, MUTATION-POSITIVE MELANOMA, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Risk Factors, 030212 general & internal medicine, Neoplasm Metastasis, Vemurafenib, Melanoma, Aged, 80 and over, education.field_of_study, Framingham Risk Score, Middle Aged, OPEN-LABEL, Prognosis, DABRAFENIB, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], clinical practice, SAFETY, 030220 oncology & carcinogenesis, SURVIVAL, Female, vemurafenib, medicine.drug, metastatic melanoma, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, PHASE-3, Population, Antineoplastic Agents, Ipilimumab, Dermatology, risk score, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, education, Aged, business.industry, Proportional hazards model, IPILIMUMAB, prognostic factors, Dabrafenib, medicine.disease, Confidence interval, REGISTRY, FOLLOW-UP, business
وصف الملف: image/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2624cc827142bef034456a349c84a18
https://hdl.handle.net/1887/96180 -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
10دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.